Previous 10 | Next 10 |
The COVID-19 pandemic continues to impact pharmaceutical markets globally, and is estimated to expand the net cumulative pharmaceutical market by $500 billion from 2020 through 2027 Highest volume growth is expected in Latin America, Asia and Africa, driven by a mix of population growth and e...
Summary iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. Healthcare and pharmaceutical shares have a strong track record of holding up during bear markets and recessions over the last 100 years. The Top 10 hold...
As we kick off 2023, there are a few signs that select stocks might be in ling for a great year. The stocks for healthcare companies IQVIA Holdings (NYSE: IQV) and Vertex Pharmaceuticals (NASDAQ: VRTX) , for example, have been on the upswing recently thanks to reports of incre...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Lasso announces a significant step forward in healthcare marketing measurement PR Newswire The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights. AUSTIN, Texas , Jan. 3, 2023 ...
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer PR Newswire IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, M...
IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the fir...
Summary William von Mueffling's 13F portfolio value decreased this quarter from $11.98B to $11.04B. Cantillon increased Microsoft, BlackRock, Entegris, and SS&C Technologies during the quarter. The portfolio continues to be very concentrated with the top five positions acc...
Summary The COVID-19 pandemic's impact on clinical trial delays has expanded the market opportunity for large, multinational CROs. IQVIA, one of the largest CROs, has real opportunities to expand its client base with its Q2 Solutions international offering, technical solutions, R&...
IQVIA Holdings (IQV) Q3 2022 Earnings Conference Call October 26, 2022, 09:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice Presid...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...